Clinical trials: Everolimus
Advanced Breast Cancer
Genetically-informed Therapy for ER+ Breast Cancer Post-CDK4/6 Inhibitor
The purpose of this study is to learn if certain drug combinations are effective treatments for patients with advanced ER+/HER2- who have previously been treated with palbociclib, ribociclib, or abemaciclib.
- Trial name
- GERTRUDE (NCT05933395)
- Testing
- Fulvestrant, Neratinib, Alpelisib
- Where
- United States
- Volunteers
- 135 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Renal Transplantation
This is a Two-year Follow-up Study to Evaluate the Long-term Safety, Tolerability and Efficacy of 2 Different Doses of Everolimus
This extension study is designed to provide long-term safety and efficacy data beyond 12 months up to Month 36.
- Trial name
- NCT00531063
- Testing
- Everolimus (RAD001)
- Where
- Switzerland
- Volunteers
- 237 people
- Sponsor
- Novartis Pharmaceuticals
Liver Transplantation
De Novo Everolimus Versus Tacrolimus in Combination With Mofetil Mycophenolate and Low Dose Corticosteroids to Reduce Tacrolimus Induced Nephrotoxicity in Liver Transplantation: a Prospective, Multicentric, Randomised Study
Tacrolimus is a calcineurin inhibitor. This is the immunosuppression of reference for patients undergoing a first liver transplant.
- Trial name
- FOREVER (NCT02909335)
- Testing
- Tacrolimus, Everolimus, Mycophenolate mofetil
- Sponsor
- Rennes University Hospital
Atherosclerosis, Coronary Artery Disease
Prospective, Randomized, Multicenter Trial to Assess PROMUS™ Element™ Stent
The purpose of this study is to evaluate the safety and effectiveness of the PROMUS™ Element™ Everolimus-Eluting Coronary Stent System for the treatment of subjects in China with a single de novo atherosclerotic coronary artery…
- Trial name
- PTChina (NCT01285999)
- Testing
- PROMUS Element Coronary Stent System, TAXUS Liberté Coronary Stent System
- Where
- 15 sites in China
- Volunteers
- 500 people
- Sponsor
- Boston Scientific Corporation
Endometrial Cancer
Letrozole and RAD001 With Advanced or Recurrent Endometrial Cancer
The goal of this clinical research study is to learn if the combination of RAD001 (everolimus) and Femara (letrozole) can help to control recurrent or progressive endometrial cancer.
- Trial name
- NCT01068249
- Testing
- Letrozole, RAD001 (Everolimus)
- Where
- 2 sites in United States
- Volunteers
- 42 people
- Sponsor
- M.D. Anderson Cancer Center
Kidney Transplantation
Effect of Different Therapeutic Strategies on Regulatory T Cells in Kidney Transplantation
The objective of the study will be to evaluate the effect of different therapeutic immunosuppressive strategies currently employed in common clinical practice on regulatory T lymphocytes and to verify the hypothesis that the…
- Trial name
- EVERTWIST (NCT01640743)
- Testing
- Tacrolimus + Methylprednisolone, Tacrolimus + Everolimus + Methylprednisolone
- Where
- Italy
- Volunteers
- 58 people
- Sponsor
- Fondazione IRCCS Policlinico San Matteo di Pavia
Hodgkin Lymphoma
Everolimus in Combination With DHAP in Patients With Relapsed or Refractory Hodgkin Lymphoma
The purpose of this trial is 1. to determine the recommended dose of everolimus for a subsequent Phase II trial 2. to determine the efficacy of everolimus plus DHAP
- Trial name
- HD-R3i (NCT01453504)
- Testing
- DHAP, Everolimus
- Where
- Germany
- Volunteers
- 73 people
- Sponsor
- University of Cologne
COVID-19 Vaccines, Varicella Zoster Vaccine
PREPARE-iVAC Trial
Objective: To investigate whether replacement of MMF/MPA by everolimus in kidney transplant recipients results in superior immunogenicity of COVID-19 vaccination as measured by neutralizing antibody titer against the Omicron…
- Conditions
- COVID-19 Vaccines, Varicella Zoster Vaccine, Vaccine Response, Immunosuppression
- Trial name
- PREPARE-iVAC (NCT05924685)
- Testing
- COVID-19 vaccination
- Where
- 7 sites in Netherlands
- Volunteers
- 110 people
- Sponsor
- University Medical Center Groningen
Recurrent Ovarian Cancer, Signal Transduction Pathway Deregulation
Signal TrAnsduction Pathway Activity Analysis in OVarian cancER
The purpose of this prospective, parallel-group, cohort study is to implement phenotype-guided targeted therapy based on functional signal transduction pathway (STP) activity in recurrent ovarian cancer patients using a novel…
- Conditions
- Recurrent Ovarian Cancer, Signal Transduction Pathway Deregulation, Therapy-Associated Cancer
- Trial name
- STAPOVER (NCT03458221)
- Testing
- Letrozole Oral Product, Bicalutamide Oral Product, Everolimus Oral Product
- Where
- 6 sites in Netherlands
- Volunteers
- 148 people
- Sponsor
- Gynaecologisch Oncologisch Centrum Zuid
Myocardial Infarction, ST Elevation Myocardial Infarction
10-Years Follow-up of the EXAMINATION Trial
The EXAMINATION trial was a superiority trial that compared everolimus-eluting stents (EES) versus bare-metal stents (BMS) in an all-comer ST-segment elevation myocardial infarction (STEMI) population.
- Conditions
- Myocardial Infarction, ST Elevation Myocardial Infarction, Infarction, Necrosis
- Trial name
- EXAMINAT10N (NCT04462315)
- Testing
- Everolimus Eluting Coronary Stent System, Cobalt chromium balloon expandable stent (non-drug-eluting stent Arm)
- Where
- 11 sites in Italy, Netherlands and 1 more
- Volunteers
- 1,498 people
- Sponsor
- Hospital Clinic of Barcelona
Hepatocellular Carcinoma
A Phase 1 Study of MM-141 in Patients With Advanced Solid Tumors
This study is a Phase 1 and pharmacologic open-labeled dose-escalation trial using a "3+3" design, evaluating MM-141 at varying dose levels and frequencies.
- Trial name
- NCT01733004
- Testing
- MM-141
- Where
- 4 sites in United States, France
- Volunteers
- 42 people
- Sponsor
- Merrimack Pharmaceuticals
Chronic Coronary Occlusion, Vascular Disease
XIENCE V® Everolimus Eluting Coronary Stent System USA Post-Approval Study (XIENCE V® USA Long Term Follow-up Cohort)
XIENCE V USA is a prospective, multi-center, multi-cohort post-approval study. The objectives of this study are To evaluate XIENCE V EECSS continued safety and effectiveness during commercial use in real world settings, and To…
- Conditions
- Chronic Coronary Occlusion, Vascular Disease, Myocardial Ischemia, Coronary Artery Stenosis
- Trial name
- XVU-LTF (NCT01120379)
- Testing
- XIENCE V® EECSS
- Where
- United States
- Volunteers
- 5,034 people
- Sponsor
- Abbott Medical Devices
Renal Transplantation
Calcineurin Inhibitor (CNI) Versus Steroid Cessation in Renal Transplantation
This study intends to determine whether steroid withdrawal or calcineurin inhibitor withdrawal is superior for graft function and graft survival.
- Trial name
- CISTCERT (NCT00903188)
- Testing
- cyclosporine, Everolimus
- Where
- 5 sites in Belgium
- Volunteers
- 152 people
- Sponsor
- University Hospital, Antwerp
Cancer
GSK1120212 Rollover Study
This was an open-label study to permit subjects with solid tumors or leukemia, who were clinically benefitting on another GSK sponsored trial with GSK1120212 either monotherapy or in combination continued access to GSK1120212.
- Trial name
- NCT01376310
- Testing
- GSK1120212, Docetaxel + GSK1120212, Erlotinib + GSK1120212
- Where
- 19 sites in United States, Canada and 4 more
- Volunteers
- 159 people
- Sponsor
- Novartis Pharmaceuticals
Tumors, Brain Tumors
Everolimus for Treating Pediatric Patients With Recurrent or Refractory Tumors
Patients with recurrent or refractory solid tumors or brain tumors that are unresponsive to conventional therapy, or with no known effective therapy, will be treated.
- Conditions
- Tumors, Brain Tumors, Rhabdomyosarcoma, Sarcoma, Soft Tissue
- Trial name
- NCT00187174
- Testing
- Everolimus
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- St. Jude Children's Research Hospital
Castrate Resistant Prostate Cancer, Chemotherapy Naive Prostate Cancer
Pasireotide (SOM230) With or Without Everolimus in Treating Patients With Hormone Resistant, Chemotherapy Naive Prostate Cancer
This is an open label randomized phase II study for prostate cancer patients who have disease progression after hormonal therapy.
- Conditions
- Castrate Resistant Prostate Cancer, Chemotherapy Naive Prostate Cancer, Prostate Cancer
- Trial name
- NCT01313559
- Testing
- Pasireotide, Everolimus, Laboratory biomarker analysis
- Where
- 2 sites in United States
- Volunteers
- 6 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Coronary Heart Disease
3 Limus Agent Eluting Stents With Different Polymer Coating
The aim of this study is to determine whether biodegradable polymer based rapamycin-eluting stent performs equal to permanent polymer based everolimus- and rapamycin-eluting stents regarding reduction of adverse cardiac events at…
- Trial name
- ISAR-TEST-4 (NCT00598676)
- Testing
- biodegradable polymer Rapamycin-eluting stent, permanent polymer rapamycin-eluting stent (Cypher), permanent polymer everolimus-eluting stent (Xience, Promus)
- Where
- 2 sites in Germany
- Volunteers
- 2,600 people
- Sponsor
- Deutsches Herzzentrum Muenchen
Gastric Cancer
Gastric Cancer RAD001 Study
The purpose of this study is to determine dose limiting toxicities (DLT) and maximum tolerated dose (MTD) of RAD001, as well as to assess tumor response and overall survival.
- Trial name
- NCT01514110
- Testing
- RAD001
- Where
- Hong Kong
- Volunteers
- 35 people
- Sponsor
- Chinese University of Hong Kong
Kidney Transplant, Immunosuppression
Prospective Cohort of Kidney Transplanted Patients Receiving an Extended Releasing Tacrolimus-Everolimus Association
The tacrolimus-Everolimus association is used as an immunospressive treatment after a kidney transplant. It combined immunosupressive properties of both products and reduce the nephrotoxicity of tacrolimus by lowering the dosage.
- Trial name
- NCT03228576
- Testing
- Extended release Tacrolimus-Everolimus association
- Where
- 9 sites in France
- Volunteers
- 16 people
- Sponsor
- Poitiers University Hospital
Coronary Artery Disease
A Comparison of Optical Coherence Tomography Guidance and Angiography-only Guidance for Percutaneous Coronary Intervention With Bioresorbable Vascular Scaffold
It is well-known that non-optimal stent implantation associated with under-expansion or incomplete strut apposition during percutaneous coronary intervention (PCI) leads to a higher incidence of restenosis and stent thrombosis.
- Trial name
- NCT02466282
- Testing
- Angiography-guided PCI with bioresorbable vascular scaffold, optical coherence tomography-guided PCI with bioresorbable vascular scaffold
- Where
- South Korea
- Volunteers
- 13 people
- Sponsor
- Yonsei University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.